Tianjin Development: Lishengpharma's mid-term net profit attributable to the parent company is 343 million yuan, an increase of 235.04% year-on-year
According to the Zhitong Finance APP, Tianjin Development announced the performance of its indirectly non-wholly-owned subsidiary Tianjin Lishengpharma Co., Ltd. (Lishengpharma) for the six months ending June 30, 2025, with total operating revenue of RMB 732 million, a year-on-year decrease of 1.76%; net profit attributable to the owners of the parent company of RMB 343 million, a year-on-year increase of 235.04%; and basic earnings per share of RMB 1.33
According to the Zhitong Finance APP, Tianjin Development (00882) announced the performance of its indirectly non-wholly-owned subsidiary Tianjin Lishengpharma Co., Ltd. (Lishengpharma) for the six months ending June 30, 2025, with total operating revenue of RMB 732 million, a year-on-year decrease of 1.76%; net profit attributable to the owners of the parent company of RMB 343 million, a year-on-year increase of 235.04%; and basic earnings per share of RMB 1.33
